Todd Tushla | VP, IR |
Kevin Gorman | CEO |
Matt Abernethy | CFO |
Eiry Roberts | Chief Medical Officer |
Eric Benevich | Chief Commercial Officer |
Kyle Gano | Chief Business Development and Strategy Officer |
Tazeen Ahmad | Bank of America |
Phil Nadeau | The Cowen Company |
Paul Matteis | Stifel |
Brian Abrahams | RBC Capital Markets |
Brian Skorney | Baird |
Jay Olson | Oppenheimer |
Neena Bitritto-Garg | Citi |
Anupam Rama | JP Morgan |
David Amsellem | Piper Sandler |
Chris Shibutani | Goldman Sachs |
Charles Duncan | Cantor Fitzgerald |
Vamil Divan | Mizuho |
Josh Schimmer | Evercore |
Myles Minter | William Blair |
Danielle Brill | Raymond James |
Laura Chico | Wedbush Securities |
Eddie Hickman | Guggenheim |
Good day, everyone, and welcome to today’s Neurocrine Biosciences Reports Second Quarter Results. At this time, all participants are in a listen-only mode. Later, you’ll have the opportunity to ask questions during the question-and-answer session. [Operator Instructions] Please note, this call may be recorded. And I will be standing by, should you need any assistance.